Abstract 417: Role of programmed cell death protein-1 (PD-1)-targeted immunotherapy in hepatocellular carcinoma

Background: Anti-programmed cell death protein-1 (PD-1) immunotherapy has shown promising outcomes in patients with advanced hepatocellular carcinoma(HCC). In practice anti-PD-1 drugs were mostly a part of combination therapy, especially in the Asia-Pacific region. We aimed to evaluate the effectiveness and safety of PD-1 inhibitors in combination therapies for HCC patients through real-world data. Methods: Between January 2018 and December 2019, patients with HCC who received anti-PD-1 immunotherapy were screened for eligibility. The primary efficacy endpoints included tumor response rate, overall survival(OS), and progression-free survival(PFS). Safety was assessed by immune-related adverse events (iAEs). Univariate and multivariate analyses were conducted to identified the risk factors of prognosis. Result: A total of 322 patients were included in our study. Anti-PD-1 immunotherapy was combined with locoregional interventional approaches (62.1%) and tyrosine kinase inhibitors TKIs (66.5%). The 3-, 6-, 12- and 18-month OS rate were 97.1%, 90.5%, 72.9%, and 57.3%, respectively. The 3-, 6-, 12- and 18-month PFS rate were 82.3%, 66.5%, 42.1%, and 30.3%, respectively. Overally, objective response rate (ORR) was 38.5%, and disease control rate (DCR) was 83.9%. The total rate of grade 3-4 treatment-related AEs was 5.9%, and laboratory-related AEs was 8.7%. Conclusion: PD-1-targeted immunotherapy as a part of a combination therapy, was a safe and effective treatment for intermediate and advanced HCC. Citation Format: Shaohua Li, Jie Mei, Qiaoxuan Wang, Wei Wei, Lianghe Lu, Jingwen Zou, Rongce Zhao, Zhixing Guo, Yihong Ling, Yuhua Wen, Wenping Lin, Lie Zheng, Minshan Chen, Rongping Guo. Role of programmed cell death protein-1 (PD-1)-targeted immunotherapy in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 417.